27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
US oncology specialist MacroGenics was trading 4% lower at lunchtime in the USA on Wednesday after presenting the final overall survival (OS) results of the SOPHIA Phase III in metastatic HER2-positive breast cancer. 8 September 2021
Indian drugmaker Hetero has announced that the Drug Controller General of India (DCGI) has issued for restricted use, Emergency Use Authorization (EUA) for the generic version of tocilizumab in India. 8 September 2021
Shares of USA-based biopharma Kadmon Holdings shot up nearly 74% to $9.21 pre-market today, after pharma major Sanofi revealed that it had reached agreement to acquire the company, which marks the fourth M&A deal for the French firm this year. 8 September 2021
Shares in Californian fibrosis specialist Pliant Therapeutics opened 14% higher on Tuesday, after the firm announced encouraging interim results from a Phase IIa trial. 8 September 2021
US drugmaker Amneal Pharmaceuticals has recently announced that its pipeline product IPX-203 (carbidopa + levodopa, (CD/LD)) achieved key primary and secondary endpoints in the pivotal Phase III RISE-PD clinical trial for patients with Parkinson’s disease (PD) who experience motor fluctuations. 8 September 2021
South Korea has recently decided to provide practical support to innovative pharmaceutical companies by revising the existing health insurance benefits system. 8 September 2021
The UK health technology assessor the National Institute of Health and Care Excellence (NICE) has reconsidered its previous decision for Erleada (apalutamide). 8 September 2021
Privately-held US early-stage gene therapy company NeuExcell Therapeutics and Spark Therapeutics, the gene therapy unit of Swiss pharma giant Roche Group, have entered a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's disease (HD). 8 September 2021
Netherlands-based AM-Pharma and Japan’s Kyowa Kirin have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase. 8 September 2021
For many years, politicians, patients and drugmakers alike have warned about the risk posed by growing antimicrobial resistance, spurred on by liberal use of antibiotics in farming, and in general medical practice. 8 September 2021
British cell therapy specialist Adaptimmune Therapeutics has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche group. 7 September 2021
Global Blood Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted for filing and review two submissions relating to Oxbryta (voxelotor). 7 September 2021
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today held a virtual press briefing with chief executives and top executives who are in the forefront of biopharmaceutical R&D for COVID-19. 7 September 2021
Sino-American company Brii Birosciences today announced that it is committing an additional $100 million to advance global regulatory filings and commercial efforts for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII-196/BRII-198. 7 September 2021
US biotech BioMarin Pharmaceutical’s shares were down more than 10% at $76.25 pre-market today, after it announced on Sunday that the US Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase I/II study. 7 September 2021
A Scotland-based company that claims to be pioneering the future of modern medicine through microbiome-modulating therapeutics now has $21.5 million more to deliver on the promise. 7 September 2021
Medicines Australia, the leading trade group for the biotech and pharma industries in the country, has helped negotiate a five-year strategic plan with the national government. 7 September 2021
Blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) has been approved by China’s National Medical Products Administration (NMPA) in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or gastroesophageal junction (GEJ). 7 September 2021
Lumevoq (lenadogene nolparvovec) has been granted Promising Innovative Medicine (PIM) designation by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). 7 September 2021